A Phase 1 / 2, Randomized, Double-Blind, Placebo-Controlled Study Designed to Evaluate the Safety, Tolerability, and Pharmacokinetics of PTI-808, PTI-801, and PTI-428 Combination Therapy in Subjects With Cystic Fibrosis
Phase of Trial: Phase I/II
Latest Information Update: 09 Sep 2019
Price : $35 *
At a glance
- Drugs PTI 428 (Primary) ; PTI 808 (Primary) ; PTI-801 Proteostasis Therapeutics (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- Sponsors Proteostasis Therapeutics
- 05 Sep 2019 Status changed from recruiting to completed.
- 07 Aug 2019 According to a Proteostasis Therapeutics media release, company announced in July about initiation of phase 2 part of the study and top line results from this study are expected in the first quarter of 2020.
- 25 Mar 2019 Results presented in the Proteostasis Therapeutics media release.